| Title |
Metformin in the Treatment of Obese Children and Adolescents at Risk of Type 2 Diabetes
|
|---|---|
| Published in |
Pediatric Drugs, August 2013
|
| DOI | 10.1007/s40272-013-0045-1 |
| Pubmed ID | |
| Authors |
Deborah L. Kendall, Rakesh Amin, Peter E. Clayton |
| Abstract |
Metformin is the first-line treatment for type 2 diabetes (T2D) in adults, children and young people, particularly in obese or overweight patients. Many studies have demonstrated that metformin is associated with weight reduction in adults and in prevention or delay of T2D onset in those who are at increased risk. In 2012, metformin was recommended by the UK National Institute for Health and Care Excellence as a treatment option in adults aged 18 years or over, who remain at high risk of T2D, despite participation in an intensive lifestyle-change programme. Prevalence of childhood obesity is increasing and is associated with elevated long-term risk of T2D and other adverse cardio-metabolic events; however, consensus is lacking on intervention strategies aimed at reducing this risk. This article discusses the rationale and evidence for the use of metformin in obese children and young people at high risk of T2D. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 63 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 2% |
| United States | 1 | 2% |
| Unknown | 61 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 12 | 19% |
| Researcher | 10 | 16% |
| Student > Ph. D. Student | 7 | 11% |
| Student > Master | 6 | 10% |
| Librarian | 4 | 6% |
| Other | 11 | 17% |
| Unknown | 13 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 25 | 40% |
| Agricultural and Biological Sciences | 7 | 11% |
| Nursing and Health Professions | 7 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 3% |
| Social Sciences | 2 | 3% |
| Other | 6 | 10% |
| Unknown | 14 | 22% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 February 2014.
All research outputs
#18,365,132
of 22,745,803 outputs
Outputs from Pediatric Drugs
#450
of 550 outputs
Outputs of similar age
#130,985
of 175,565 outputs
Outputs of similar age from Pediatric Drugs
#8
of 8 outputs
Altmetric has tracked 22,745,803 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 550 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.5. This one is in the 8th percentile – i.e., 8% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 175,565 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 8 others from the same source and published within six weeks on either side of this one.